It looks very likely TransFatty will make the New Year and cause the pacer intervention internet cohort to edge ahead of the nonpacer intervention internet cohort during the event called New Year's Day . . .

TransFatty
TransFatty Lives (2015) - IMDb
Trans is currently working on a new film from his abode Admiral Hill in Chelsea, Massachusetts.

The updates summary statistics will look like:
update alpha als - Google Drive

and already shows the pacer intervention cohort leading the unknown (dk) group in the thresholds with multiple publications . . . strictly speaking the twenty year threshold is tied by raw count at six patients each but there are 181 patients discovered who disclosed their pacer intervention and 234 patients who expressed an interest in the pacer intervention but who have no known internet disclosure on whether they actually underwent the procedure.

This news is good as it shows the pacer remains strong candidate for best intervention so far discovered but implant timing is critical . . . too soon, implant may be less than optimal, too late and much of its value may be lost.

DiPALS reported issues with their study on the pacer but have yet to profile any case in particular. Hopefully, their negative sounding report is a false negative. Emerging interventions have been known to have false negative study results, riluzole has one example . . .

Here are two references:

Frequency, timing and outcome of gastrostomy tubes for amyotrophic lateral sclerosis/motor neurone disease--a record linkage study from the Scottish Motor Neurone Disease Register
Frequency, timing and outcome of gastrostomy tubes for amyotrophic lateral sclerosis/motor neurone disease--a record linkage study from the Scottish Motor Neurone Disease Register - PubMed
" . . . The 1 month mortality after gastrostomy was 25% . . . "

[Neuroprotective therapy for amyotrophic lateral sclerosis (ALS)]
[Neuroprotective therapy for amyotrophic lateral sclerosis (ALS)] - PubMed
" . . . but the effects were insignificant in the Japanese nation-wide trial."

Regarding riluzole in Amyotrophic Lateral Sclerosis, regarded as +three moon shift in survival medians; survival term improvement from gastrostomy is unclear.